AnaptysBio, Inc.
http://www.anaptysbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AnaptysBio, Inc.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.
Deal Watch: Vanda Buys US, Canadian Rights To J&J’s Ponvory
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.
Anaptys Partner Search Boosted By Phase III Skin Disease Success
After disappointments in other indications, notably hidradenitis suppurativa, AnaptysBio has posted positive Phase III results for its IL-36 receptor-targeting monoclonal antibody imsidolimab in generalized pustular psoriasis.
BI Prepares For Regulatory Filings After Spevigo Successfully Prevents GPP Flares
The German firm’s Spevigo seems set to dominate the generalized pustular psoriasis market after it reduced the risk of flares in the pivotal EFFISAYIL 2 trial, triggering label expansion plans less than a year after it was approved for flare treatment.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice